The Epithalon sequence is commonly written as Ala-Glu-Asp-Gly, or AEDG. Those four letters identify the order of four amino-acid residues. For a fuller chemical description, the terminal groups and any modifications matter too.
This guide focuses on reading an Epithalon identity record. It does not assess longevity claims or provide instructions for using a research material.
Translate AEDG one position at a time
The PubChem Epitalon record lists Epithalon as a synonym and gives the sequence AEDG. Its expanded description is H-Ala-Glu-Asp-Gly-OH.
- A / Ala: alanine, first in this sequence
- E / Glu: glutamic acid, second
- D / Asp: aspartic acid, third
- G / Gly: glycine, fourth
Read from the amino-terminal end toward the carboxyl-terminal end, conventionally left to right. In this example, alanine is at the N-terminus and glycine is at the C-terminus. The IUPAC one-letter notation recommendations explain the residue codes and sequence direction.
The end labels are not extra amino acids
In H-Ala-Glu-Asp-Gly-OH, the outer H- and -OH make the unmodified amino and carboxyl ends explicit. The molecule still contains four residues. The H- here does not add histidine, whose three-letter symbol would be His.
PubChem also supplies a molecular formula and a specified structure. These describe the database's chemical entity; they do not certify what is in a particular vial. A useful comparison records the sequence and structure identifier together rather than treating the shortest name as a complete specification.
Changing a terminal group changes the description
A prefix such as Ac- indicates an acetyl substituent. A terminal -NH2 indicates an amide instead of the corresponding free carboxyl end. These conventions are set out in the IUPAC peptide-symbolism recommendations.
For a notation exercise, compare H-Ala-Glu-Asp-Gly-OH with Ac-Ala-Glu-Asp-Gly-OH. The four residue names remain in the same order, but the N-terminal description differs. This is a hypothetical comparison, not a statement that Dissolv supplies an acetylated version. Nor does a changed label by itself predict a particular biological effect.
Keep acetate separate from acetylation
The word acetate in a salt description does not mean that an Ac- group has been covalently attached to the peptide's N-terminus. Salt form and terminal substitution belong in separate fields when comparing records.
This distinction has practical relevance for Epithalon. FDA's 2026 Epitalon briefing document evaluated the free-base and acetate descriptions separately and noted that publications did not always make the form clear. A shared compound name can therefore leave a material-identity question unresolved.
A compact identity-check worksheet
When reading a paper or reviewing research-material documentation, write down these five items before deciding that two entries match:
- The complete name, including any alternate spelling used by the source
- The residue order, expanded from AEDG when necessary
- The N-terminal and C-terminal descriptions
- Any salt, stereochemical, or linkage qualifications explicitly stated
- The source document and lot identifier, or a clear note that the information is missing
Missing information should stay marked as missing. Do not silently fill it from another supplier's page or from the database entry. This makes the comparison auditable and keeps an assumed match from becoming a reported fact.
The Dissolv catalog reference
The Epithalon 10mg catalog listing is the relevant Dissolv product page. This article has not verified its lot-specific terminal chemistry or salt form. Confirm those details through documentation for the actual material.
Research use only. This item is not for human or veterinary use. Sequence notation and database identifiers do not establish safety, efficacy, or clinical suitability.
